Free Newsletter
Agency lures biotechs with $20M for stem cell teams
California's stem cell agency is mapping out ambitious plans to provide $20 million to each of 10 to 12 research teams that can be in the clinic with a new therapy inside of four years. And the agency's chief expects a biotech company to be included in the teams.
Agency president Alan Trounson says that it's time to start moving stem cell work out of the lab and into human trials. And he says that this is the right time to partner up with biopharma companies that are being lured into the stem cell field.
"Pharma is moving into this space in a big way," Trounson told Bloomberg in an interview. "They're now generally interested in cell therapy. That's a big change."
California's Institute of Regenerative Medicine has spurred big joint investments in new research facilities in the state, leveraging its $3 billion in grant money in partnerships with state universities. But after the $3 billion runs out, the agency may be able to continue to operate using industry funds. And these initial stem cell teams are a step in that direction.
- read the report from Bloomberg
Related Articles:
California's stem cell boom spurs research bonanza
California's stem cell agency is running out of cash
Stem cell agency forced to delay $58M in grants
CIRM offers $59M to inspire young scientists
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession




